Fig. 1 · Structure

Documents & Downloads

Hematoxylin (Hydroxybrazilin)

Cat. No. A10447 CAS 517-28-2
Haematoxylin is extracted from the heartwood of the logwood tree.When oxidized it forms haematein, a compound that forms strongly coloured complexes with certain metal ions, the most notable ones being Fe(III) and Al(III) salts. Metal-haematein complexes are used to stain cell nuclei prior to examination under a microscope.

In Stock

Publications for Hematoxylin

1 publication citing this product

  1. Yuanwei Liu, .et al. , Pathol Res Pract, 2024, Oct:262:155544 PMID: 39197215

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

In a lysate thermal-shift assay, hematoxylin stabilized both WT and mutant CALR, with MPL serving as a comparison protein. These results support CALR engagement without demonstrating mutant-selective binding or a quantitative binding affinity. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Cellular Effect

Cell Line Activity Value Description Reference
HeLa IC50 1.3 μM Inhibition of HIV1 VPR/human importin-alpha interaction in human HeLa cells assessed as inhibition of nuclear import of preintegral complex after 15 mins by confocal laser scanning microscopic analysis [PMID: 22244940]
MOLT-4 CC50 40 μM Cytotoxicity against human MOLT4 cells expressing CD4+ after 2 days by MTT assay [PMID: 22244940]

Hematoxylin (Hydroxybrazilin) Research Summary

This section summarizes 2 in vitro studies of Hematoxylin (Hydroxybrazilin) from 1 published reference.

Hematoxylin (Hydroxybrazilin) In Vitro Studies

Hematoxylin reduced 72-hour viability in CALR-mutant Ba/F3-MPL and UT-7/TPO cells at lower reported IC50 values than their WT comparators. The difference was smaller in the human UT-7/TPO model; differing cytokine conditions limit conclusions about genotype selectivity from these monoculture assays. [1]

CALR genotype-associated viability responses

Cell-based study · Murine Ba/F3-MPL CALR WT, del79/WT and del37/del37 cells; human UT-7/TPO CALR WT and heterozygous mutant cells (del58/WT in Figure 2D). [1]

At 72 hours, hematoxylin reduced CellTiter-Glo viability with lower reported IC50 values in mutant-CALR models than WT comparators. The separation was smaller in the human UT-7/TPO model. WT and mutant monocultures had different cytokine conditions, which limits interpretation of genotype selectivity from these dose-response experiments alone.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
72-hour CellTiter-Glo viability in CALR-mutant Ba/F3-MPL cellsIC50 2.90 ± 0.67 μM[1]
72-hour CellTiter-Glo viability in CALR-WT Ba/F3-MPL cellsIC50 11.18 ± 2.87 μM[1]
72-hour CellTiter-Glo viability in CALR-mutant UT-7/TPO cellsIC50 16.01 ± 2.27 μM[1]
72-hour CellTiter-Glo viability in CALR-WT UT-7/TPO cellsIC50 33.61 ± 3.28 μM[1]

Literature-Reported Treatment Conditions

Treatment concentration
Hematoxylin concentration-response series; the full list of individual tested concentrations is not tabulated in the acquired main text.
Exposure duration
72 hours
Method
CellTiter-Glo luminescent cell viability assay. WT cells received 1% TPO-conditioned medium; CALR-mutant cells were assayed without cytokine.
Vehicle
DMSO; all drug-treatment groups contained equal amounts of DMSO (Figure 2C–D caption).
Reported limits
Exact DMSO percentage and full concentration-point list were not established from the acquired main text. Figure 2C–D reports n = 6; the experimental unit and the aggregation used for the reported mutant IC50 are not explicit. ± values are retained as reported; the figure describes mean ± SD, without separately defining uncertainty for fitted IC50 values.
Methods and source locations

Compound reported in the paper: Hematoxylin; Compound label in the paper: Hematoxylin

Evidence concerns the hematoxylin tested by Jia et al.; it does not validate an Adooq lot, purity or stereochemical composition.

Methods: Cell viability assay; Results: Identification of compounds that selectively reduce the viability of CALR-mutant cells; Figure 2C–D and caption

72-hour CellTiter-Glo viability in CALR-mutant Ba/F3-MPL cells: Luminescent cell viability assay; reported mutant IC50 summary. — Results: Identification of compounds that selectively reduce the viability of CALR-mutant cells; Figure 2C

72-hour CellTiter-Glo viability in CALR-WT Ba/F3-MPL cells: Luminescent cell viability assay. — Results: Identification of compounds that selectively reduce the viability of CALR-mutant cells; Figure 2C

72-hour CellTiter-Glo viability in CALR-mutant UT-7/TPO cells: Luminescent cell viability assay. — Results: Identification of compounds that selectively reduce the viability of CALR-mutant cells; Figure 2D

72-hour CellTiter-Glo viability in CALR-WT UT-7/TPO cells: Luminescent cell viability assay. — Results: Identification of compounds that selectively reduce the viability of CALR-mutant cells; Figure 2D

Thermal stabilization of CALR in cell lysates

Biochemical assay · Lysates of HEK293T cells transiently expressing CALR ins5, WT CALR or MPL. [1]

Hematoxylin increased thermal stability of both mutant and WT CALR relative to DMSO; MPL did not show comparable stabilization. This lysate assay supports CALR engagement but does not establish mutant-selective binding, a binding constant or an in vivo exposure requirement.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Soluble CALR after thermal challengeQualitative thermal stabilization Thermal stabilization of CALR ins5 and WT CALR versus DMSO; no comparable MPL stabilization reported.[1]

Literature-Reported Treatment Conditions

Treatment concentration
1 mM hematoxylin for the temperature series; 10 μM, 100 μM and 1 mM for the CALR ins5 concentration series shown in Figure 4G.
Exposure duration
30-minute lysate incubation on ice, followed by 6-minute heating at the indicated temperatures.
Method
Hematoxylin or DMSO was added to lysates after cellular expression. The temperature-series blot is labeled 45, 50, 55, 60, 65, 70 and 75 °C; concentration-series blots are labeled 45, 49 and 54 °C.
Vehicle
DMSO control
Reported limits
No fitted melting-temperature shift, binding affinity, replicate count or final DMSO percentage is specified for Figure 4G in the acquired main text. Supplementary details were not retrieved.
Methods and source locations

Compound reported in the paper: Hematoxylin; Compound label in the paper: HEM

Evidence concerns the hematoxylin tested by Jia et al.; it does not validate an Adooq lot, purity or stereochemical composition.

Methods: CETSA; Results: Hematoxylin binds to CALR and disrupts CALR-MPL interaction; Figure 4G and caption

Soluble CALR after thermal challenge: Cellular thermal shift assay performed on transfected-cell lysates; soluble proteins detected by western blot. — Methods: CETSA; Results: Hematoxylin binds to CALR and disrupts CALR-MPL interaction; Figure 4G and caption

Specifications

Manufacturer Adooq Bioscience
CAS Number 517-28-2
Formula C16H14O6
Molecular Weight 302.3
Synonyms Natural Black 1; C.I. 75290; Hydroxybrazilin
SMILES
Oc1cc2c(cc1O)[C@@H]1c3ccc(O)c(O)c3OC[C@]1(O)C2

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 54 mg/mL (178.63 mM)
Water 54 mg/mL (178.63 mM)
Ethanol 54 mg/mL (178.63 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Hematoxylin (Hydroxybrazilin) Research References

  1. [1] Ruochen Jia, Thomas Balligand, Vasyl Atamanyuk, et al. Hematoxylin binds to mutant calreticulin and disrupts its abnormal interaction with thrombopoietin receptor Blood (2021). PMID: 33202418 DOI: 10.1182/blood.2020006264 Source material

Publications

1 publication citing this product

  1. Yuanwei Liu, .et al. , Pathol Res Pract, 2024, Oct:262:155544 PMID: 39197215

Added to your cart

View Cart Checkout
Loading...